HCB101, a third-generation CD47-SIRPα inhibitor, binds CD47 with high affinity, potently stimulates macrophage-mediated tumor cell phagocytosis without erythrocyte toxicity, increases the anti-tumoral/pro-tumoral macrophage ratio in the TME indicating pro-inflammatory repolarization, and significantly suppresses tumor growth [148]. Here, SIRPA is linked to neoplasm.